nach oben

Erschienen in:

01.03.2009

Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL)

verfasst von: Shiv Kumar Sarin, Ashish Kumar, John A. Almeida, Yogesh Kumar Chawla, Sheung Tat Fan, Hitendra Garg, H. Janaka de Silva, Saeed Sadiq Hamid, Rajiv Jalan, Piyawat Komolmit, George K. Lau, Qing Liu, Kaushal Madan, Rosmawati Mohamed, Qin Ning, Salimur Rahman, Archana Rastogi, Stephen M. Riordan, Puja Sakhuja, Didier Samuel, Samir Shah, Barjesh Chander Sharma, Praveen Sharma, Yasuhiro Takikawa, Babu Ram Thapa, Chun-Tao Wai, Man-Fung Yuen

Erschienen in: Hepatology International | Ausgabe 1/2009

Einloggen, um Zugang zu erhalten

Abstract

The Asian Pacific Association for the Study of the Liver (APASL) set up a working party on acute-on-chronic liver failure (ACLF) in 2004, with a mandate to develop consensus guidelines on various aspects of ACLF relevant to disease patterns and clinical practice in the Asia-Pacific region. Experts predominantly from the Asia–Pacific region constituted this working party and were requested to identify different issues of ACLF and develop the consensus guidelines. A 2-day meeting of the working party was held on January 22–23, 2008, at New Delhi, India, to discuss and finalize the consensus statements. Only those statements that were unanimously approved by the experts were accepted. These statements were circulated to all the experts and subsequently presented at the Annual Conference of the APASL at Seoul, Korea, in March 2008. The consensus statements along with relevant background information are presented in this review.

No consensus.

Centre for evidence-based medicine. Levels of evidence. 2001. http://www.cebm.net/index.aspx?o=1047. Accessed 12 Oct 2008

Ohnishi H, Sugihara J, Moriwaki H, Muto Y. Acute-on-chronic liver failure. Ryoikibetsu Shokogun Shirizu 1995;(7):217–219

O’Grady JG, Schalm SW, Williams R. Acute liver failure: redefining the syndromes. Lancet 1993;342:273–275PubMedCrossRef

Bernuau J, Rueff B, Benhamou JP. Fulminant and subfulminant liver failure: definitions and causes. Semin Liver Dis 1986;6:97–106PubMedCrossRef

Gimson AE, O’Grady J, Ede RJ, Portmann B, Williams R. Late onset hepatic failure: clinical, serological and histological features. Hepatology 1986;6:288–294PubMedCrossRef

Lee WM, Squires RH Jr, Nyberg SL, Doo E, Hoofnagle JH. Acute liver failure: summary of a workshop. Hepatology 2008;47:1401–1415PubMedCrossRef

Kohrt HE, Ouyang DL, Keeffe EB. Antiviral prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Clin Liver Dis 2007;11:965–991PubMedCrossRef

Millonig G, Kern M, Ludwiczek O, Nachbaur K, Vogel W. Subfulminant hepatitis B after infliximab in Crohn’s disease: need for HBV-screening? World J Gastroenterol 2006;12:974–976PubMed

Sheng WH, Kao JH, Chen PJ, Huang LM, Chang SY, Sun HY, et al. Evolution of hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy. Clin Infect Dis 2007;45:1221–1229PubMedCrossRef

10.

Paitoonpong L, Suankratay C. Immunological response to hepatitis B vaccination in patients with AIDS and virological response to highly active antiretroviral therapy. Scand J Infect Dis 2008;40:54–58PubMedCrossRef

11.

Flink HJ, Sprengers D, Hansen BE, van Zonneveld M, de Man RA, Schalm SW, et al. Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon {alpha}-2b therapy. Gut 2005;54:1604–1609PubMedCrossRef

12.

Perceau G, Diris N, Estines O, Derancourt C, Lévy S, Bernard P. Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma. Br J Dermatol 2006;155:1053–1056PubMedCrossRef

13.

Sera T, Hiasa Y, Michitaka K, Konishi I, Matsuura K, Tokumoto Y, et al. Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Intern Med 2006;45:721–724PubMedCrossRef

14.

Locasciulli A, Bruno B, Alessandrino EP, Meloni G, Arcese W, Bandini G, et al. Hepatitis reactivation and liver failure in haemopoietic stem cell transplants for hepatitis B virus (HBV)/hepatitis C virus (HCV) positive recipients: a retrospective study by the Italian group for blood and marrow transplantation. Bone Marrow Transplant 2003;31:295–300PubMedCrossRef

15.

Hsieh CY, Huang HH, Lin CY, Chung LW, Liao YM, Bai LY, et al. Rituximab-induced hepatitis C virus reactivation after spontaneous remission in diffuse large B-cell lymphoma. J Clin Oncol 2008;26:2584–2586PubMedCrossRef

16.

Hamid SS, Atiq M, Shehzad F, Yasmeen A, Nissa T, Salam A, et al. Hepatitis E virus superinfection in patients with chronic liver disease. Hepatology 2002;36:474–478PubMedCrossRef

17.

Ramachandran J, Eapen CE, Kang G, Abraham P, Hubert DD, Kurian G, et al. Hepatitis E superinfection produces severe decompensation in patients with chronic liver disease. J Gastroenterol Hepatol 2004;19:134–138PubMedCrossRef

18.

Monga R, Garg S, Tyagi P, Kumar N. Superimposed acute hepatitis E infection in patients with chronic liver disease. Indian J Gastroenterol 2004;23:50–52PubMed

19.

Kumar M, Sharma BC, Sarin SK. Hepatitis E virus as an etiology of acute exacerbation of previously unrecognized asymptomatic patients with hepatitis B virus-related chronic liver disease. J Gastroenterol Hepatol 2008;23(6):83–87CrossRef

20.

Acharya SK, Sharma PK, Singh R, Mohanty SK, Madan K, Jha JK, et al. Hepatitis E virus (HEV) infection in patients with cirrhosis is associated with rapid decompensation and death. J Hepatol 2007;46:387–394CrossRef

21.

Chung RT, Friedman LS. Bacterial, parasitic, and fungal infections of the liver, including liver abscess. In Feldman M, Friedman LS, Brandt LJ, editors. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease. 8th ed. Philadelphia: WB Saunders; 2006. p. 1731

22.

Laleman W, Wilmer A, Evenepoel P, Elst IV, Zeegers M, Zaman Z, et al. Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure. Crit Care 2006;10:R108PubMedCrossRef

23.

Sen S, Davies NA, Mookerjee RP, Cheshire LM, Hodges SJ, Williams R, et al. Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: a randomized controlled study. Liver Transpl 2004;10:1109–1119PubMedCrossRef

24.

Hessel FP, Mitzner SR, Rief J, Guellstorff B, Steiner S, Wasem J. Economic evaluation and 1-year survival analysis of MARS in patients with alcoholic liver disease. Liver Int 2003;23(Suppl 3):66–72PubMed

25.

Lee KH, Lee MK, Sutedja DS, Lim SG. Outcome from molecular adsorbent recycling system (MARS) liver dialysis following drug-induced liver failure. Liver Int 2005;25:973–977PubMedCrossRef

26.

Mattéi A, Rucay P, Samuel D, Feray C, Reynes M, Bismuth H. Liver transplantation for severe acute liver failure after herbal medicine (Teucrium polium) administration. J Hepatol 1995;22:597PubMedCrossRef

27.

Ripoll C, Groszmann R, Garcia-Tsao G, Grace N, Burroughs A, Planas R, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 2007;133:481–488PubMedCrossRef

28.

del Olmo JA, Flor-Lorente B, Flor-Civera B, Rodriguez F, Serra MA, Escudero A, et al. Risk factors for nonhepatic surgery in patients with cirrhosis. World J Surg 2003;27:647–652PubMedCrossRef

29.

Rice HE, O’Keefe GE, Helton WS, Johansen K. Morbid prognostic features in patients with chronic liver failure undergoing nonhepatic surgery. Arch Surg 1997;132:880–884PubMed

30.

Cholongitas E, Senzolo M, Patch D, Kwong K, Nikolopoulou V, Leandro G, et al. Risk factors, sequential organ failure assessment and model for end-stage liver disease scores for predicting short term mortality in cirrhotic patients admitted to intensive care unit. Aliment Pharmacol Ther 2006;23:883–893PubMedCrossRef

31.

Wehler M, Kokoska J, Reulbach U, Hahn EG, Strauss R. Short-term prognosis in critically ill patients with cirrhosis assessed by prognostic scoring systems. Hepatology 2001;34:255–261PubMedCrossRef

32.

Wasmuth HE, Kunz D, Yagmur E, Timmer-Stranghöner A, Vidacek D, Siewert E, et al. Patients with acute on chronic liver failure display “sepsis-like” immune paralysis. J Hepatol 2005;42:195–201PubMedCrossRef

33.

Mitzner SR, Stange J, Klammt S, Risler T, Erley CM, Bader BD, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000;6:277–286PubMedCrossRef

34.

Heemann U, Treichel U, Loock J, Philipp T, Gerken G, Malago M, et al. Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology 2002;36:949–958PubMed

35.

Zauner C, Schneeweiss B, Schneider B, Madl C, Klos H, Kranz A, et al. Short-term prognosis in critically ill patients with liver cirrhosis: an evaluation of a new scoring system. Eur J Gastroenterol Hepatol 2000;12:517–522PubMedCrossRef

36.

Choi JY, Bae SH, Yoon SK, Cho SH, Yang JM, Han JY, et al. Preconditioning by extracorporeal liver support (MARS) of patients with cirrhosis and severe liver failure evaluated for living donor liver transplantation—a pilot study. Liver Int 2005;25:740–745PubMedCrossRef

37.

Wagholikar GD, Lee KH, Pandey D, Leong SO, Singh R, Tan KC. Pre-transplant optimization by molecular adsorbent recirculating system in patients with severely decompensated chronic liver disease. Indian J Gastroenterol 2007;26:110–112PubMed

38.

Wai CT, Lim SG, Aung MO, Lee YM, Sutedja DS, Dan YY, et al. MARS: a futile tool in centres without active liver transplant support. Liver Int 2007;27:69–75PubMed

39.

Du WB, Li LJ, Huang JR, Yang Q, Liu XL, Li J, et al. Effects of artificial liver support system on patients with acute or chronic liver failure. Transplant Proc 2005;37:4359–4364PubMedCrossRef

40.

Polson J, Lee WM, American Association for the Study of Liver Disease. AASLD position paper: the management of acute liver failure. Hepatology 2005;41:1179–1197PubMedCrossRef

41.

Sen S, Williams R, Jalan R. The pathophysiological basis of acute-on-chronic liver failure. Liver 2002;22(Suppl 2):5–13PubMed

42.

Jalan R, Williams R. Acute-on-chronic liver failure: pathophysiological basis of therapeutic options. Blood Purif 2002;20:252–261PubMedCrossRef

43.

Stadlbauer V, Krisper P, Aigner R, Haditsch B, Jung A, Lackner C, et al. Effect of extracorporeal liver support by MARS and Prometheus on serum cytokines in acute-on-chronic liver failure. Crit Care 2006;10:R169PubMedCrossRef

44.

Liu Q, Liu Z, Wang T, Wang Q, Shi X, Dao W. Characteristics of acute and sub-acute liver failure in China: nomination, classification and interval. J Gastroenterol Hepatol 2007;22:2101–2106PubMedCrossRef

45.

Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000;343:1467–1476PubMedCrossRef

46.

Mookerjee RP, Stadlbauer V, Lidder S, Wright GA, Hodges SJ, Davies NA, et al. Neutrophil dysfunction in alcoholic hepatitis superimposed on cirrhosis is reversible and predicts the outcome. Hepatology 2007;46:831–840PubMedCrossRef

47.

Mookerjee RP, Dalton RN, Davies NA, Hodges SJ, Turner C, Williams R, et al. Inflammation is an important determinant of levels of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) in acute liver failure. Liver Transpl 2007;13:400–405PubMedCrossRef

48.

Lluch P, Mauricio MD, Vila JM, Segarra G, Medina P, Del Olmo JA, et al. Accumulation of symmetric dimethylarginine in hepatorenal syndrome. Exp Biol Med (Maywood) 2006;231:70–75

49.

Vizzutti F, Romanelli RG, Arena U, Rega L, Brogi M, Calabresi C, et al. ADMA correlates with portal pressure in patients with compensated cirrhosis. Eur J Clin Invest 2007;37:509–515PubMedCrossRef

50.

Lluch P, Torondel B, Medina P, Segarra G, Del Olmo JA, Serra MA, et al. Plasma concentrations of nitric oxide and asymmetric dimethylarginine in human alcoholic cirrhosis. J Hepatol 2004;41:55–59PubMedCrossRef

51.

Mookerjee RP, Malaki M, Davies NA, Hodges SJ, Dalton RN, Turner C, et al. Increasing dimethylarginine levels are associated with adverse clinical outcome in severe alcoholic hepatitis. Hepatology 2007;45:62–71PubMedCrossRef

52.

Ambrosino G, Naso A, Feltracco P, Carraro P, Basso SM, Varotto S, et al. Cytokines and liver failure: modification of TNF-α and IL–6 in patients with acute on chronic liver decompensation treated with molecular adsorbent recycling system (MARS). Acta Biomed 2003;74(Suppl 2):7–9PubMed

53.

Auth MK, Kim HS, Beste M, Bonzel KE, Baumann U, Ballauff A, et al. Removal of metabolites, cytokines and hepatic growth factors by extracorporeal liver support in children. J Pediatr Gastroenterol Nutr 2005;40:54–59PubMedCrossRef

54.

Rolando N, Wade J, Davalos M, Wendon J, Philpott-Howard J, Williams R. The systemic inflammatory response syndrome in acute liver failure. Hepatology 2000;32:734–739PubMedCrossRef

55.

Marsden PA, Ning Q, Fung LS, Luo X, Chen Y, Mendicino M, et al. The Fgl2/fibroleukin prothrombinase contributes to immunologically mediated thrombosis in experimental and human viral hepatitis. J Clin Invest 2003;112:58–66PubMed

56.

Zhu CL, Yan WM, Zhu F, Zhu YF, Xi D, Tian DY, et al. Fibrinogen-like protein 2 fibroleukin expression and its correlation with disease progression in murine hepatitis virus type 3-induced fulminant hepatitis and in patients with severe viral hepatitis B. World J Gastroenterol 2005;11:6936–6940PubMed

57.

Bosch J, García-Pagán JC. Complications of cirrhosis. I. Portal hypertension. J Hepatol 2000;32(1 Suppl):141–156PubMedCrossRef

58.

Newby DE, Jalan R, Masumori S, Hayes PC, Boon NA, Webb DJ. Peripheral vascular tone in patients with cirrhosis: role of the renin-angiotensin and sympathetic nervous systems. Cardiovasc Res 1998;38:221–228PubMedCrossRef

59.

Kumar A, Das K, Sharma P, Mehta V, Sharma BC, Sarin SK. Hemodynamic studies in acute-on-chronic liver failure. Dig Dis Sci 2008 Aug 9. [Epub ahead of print]

60.

Catalina MV, Barrio J, Anaya F, Salcedo M, Rincón D, Clemente G, et al. Hepatic and systemic haemodynamic changes after MARS in patients with acute on chronic liver failure. Liver Int 2003;23(Suppl 3):39–43PubMed

61.

Rastogi A, Sakhuja P, Gondal R, Garg H, Hissar SS, Sarin SK. Liver biopsy is a good predictor of the outcome in patients with acute on chronic liver failure [abstract]. Hepatology 2008;48(Suppl):446A

62.

Sakhuja P, Rastogi A, Gondal R, Garg H, Sarin SK. Acute on chronic liver failure—analysis of two distinct liver histological patterns [abstract]. J Hepatol 2008;48(Suppl 2):S95CrossRef

63.

Zauner CA, Apsner RC, Kranz A, Kramer L, Madl C, Schneider B, et al. Outcome prediction for patients with cirrhosis of the liver in a medical ICU: a comparison of the APACHE scores and liver-specific scoring systems. Intensive Care Med 1996;22:559–563PubMedCrossRef

64.

Sarin SK, Kumar A, Garg HK. Clinical profile of acute on chronic liver failure (ACLF) and predictors of mortality: a study of 64 patients [abstract]. Hepatology 2008;48(Suppl):450A

65.

Sakka SG, Reinhart K, Meier-Hellmann A. Prognostic value of the indocyanine green plasma disappearance rate in critically ill patients. Chest 2002;122:1715–1720PubMedCrossRef

66.

Thabut D, Massard J, Gangloff A, Carbonell N, Francoz C, Nguyen-Khac E, et al. Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure. Hepatology 2007;46:1872–1882PubMedCrossRef

67.

Antoniades CG, Berry PA, Bruce M, Cross TJ, Portal AJ, Hussain MJ, et al. Actin-free Gc globulin: a rapidly assessed biomarker of organ dysfunction in acute liver failure and cirrhosis. Liver Transpl 2007;13:1254–1261PubMedCrossRef

68.

Sharma R, Gaze DC, Pellerin D, Mehta RL, Gregson H, Streather CP, et al. Ischemia-modified albumin predicts mortality in ESRD. Am J Kidney Dis 2006;47:493–502PubMedCrossRef

69.

Collinson PO, Gaze DC, Bainbridge K, Morris F, Morris B, Price A, et al. Utility of admission cardiac troponin and “ischemia modified albumin” measurements for rapid evaluation and rule out of suspected acute myocardial infarction in the emergency department. Emerg Med J 2006;23:256–261PubMedCrossRef

70.

Inoue T, Fuke H, Yamamoto N, Ito K, Yutaka KY, Yamanaka SK. Lamivudine for treatment of spontaneous exacerbation and reactivation after immunosuppressive therapy in patients with hepatitis B virus infection. Hepatogastroenterology 2007;54:889–891PubMed

71.

Liao CA, Lee CM, Wu HC, Wang MC, Lu SN, Eng HL. Lamivudine for the treatment of hepatitis B virus reactivation following chemotherapy for non-Hodgkin’s lymphoma. Br J Haematol 2002;116:166–169PubMedCrossRef

72.

Hsu C, Hsiung CA, Su IJ, Hwang WS, Wang MC, Lin SF, et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin’s lymphoma: a randomized trial. Hepatology 2008;47:844–853PubMedCrossRef

73.

Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996;24:711–713PubMedCrossRef

74.

Zoulim F, Perrillo R. Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol 2008;48(Suppl 1):S2–S19PubMedCrossRef

75.

Guo LM, Liu JY, Xu DZ, Li BS, Han H, Wang LH, et al. Application of molecular adsorbents recirculating system to remove NO and cytokines in severe liver failure patients with multiple organ dysfunction syndrome. Liver Int 2003;23(Suppl 3):16–20PubMed

76.

Khuroo MS, Khuroo MS, Farahat KL. Molecular adsorbent recirculating system for acute and acute-on-chronic liver failure: a meta-analysis. Liver Transpl 2004;10:1099–1106PubMedCrossRef

77.

Li LJ, Yang Q, Huang JR, Xu XW, Chen YM, Fu SZ. Effect of artificial liver support system on patients with severe viral hepatitis: a study of four hundred cases. World J Gastroenterol 2004;10:2984–2988PubMed

78.

Wai CT, Da Costa M, Sutedja D, Lee YM, Lee KH, Tan KC, et al. Long-term results of liver transplant in patients with chronic viral hepatitis-related liver disease in Singapore. Singapore Med J 2006;47:588–591PubMed

79.

Stärkel P, Horsmans Y, Geubel A, Ciccarelli O, Goubau P, Rahier J, et al. Favorable outcome of orthotopic liver transplantation in a patient with subacute liver failure due to the emergence of a hepatitis B YMDD escape mutant virus. J Hepatol 2001;35:679–681PubMedCrossRef

80.

Saab S, Kim M, Wright TL, Han SH, Martin P, Busuttil RW. Successful orthotopic liver transplantation for lamivudine-associated YMDD mutant hepatitis B virus. Gastroenterology 2000;119:1382–1384PubMedCrossRef

81.

Osborn MK, Han SH, Regev A, Bzowej NH, Ishitani MB, Tran TT, et al. Outcomes of patients with hepatitis B who developed antiviral resistance while on the liver transplant waiting list. Clin Gastroenterol Hepatol 2007;5:1454–1461PubMedCrossRef

82.

Liu CL, Fan ST, Lo CM, Wei WI, Yong BH, Lai CL, et al. Live-donor liver transplantation for acute-on-chronic hepatitis B liver failure. Transplantation 2003;76:1174–1179PubMedCrossRef

83.

Andreu M, Sola R, Sitges-Serra A, Alia C, Gallen M, Vila MC, et al. Risk factors for spontaneous bacterial peritonitis in cirrhotic patients with ascites. Gastroenterology 1993;104:1133–1138PubMed

84.

Ginès A, Escorsell A, Ginès P, Saló J, Jiménez W, Inglada L, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993;105:229–236PubMed

85.

Rolando N, Harvey F, Brahm J, Philpott-Howard J, Alexander G, Gimson A, et al. Prospective study of bacterial infection in acute liver failure: an analysis of fifty patients. Hepatology 1990;11:49–53PubMedCrossRef

86.

Rolando N, Harvey F, Brahm J, Philpott-Howard J, Alexander G, Casewell M, et al. Fungal infection: a common, unrecognised complication of acute liver failure. J Hepatol 1991;12:1–9PubMedCrossRef

Titel: Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL)
verfasst von: Shiv Kumar Sarin
Ashish Kumar
John A. Almeida
Yogesh Kumar Chawla
Sheung Tat Fan
Hitendra Garg
H. Janaka de Silva
Saeed Sadiq Hamid
Rajiv Jalan
Piyawat Komolmit
George K. Lau
Qing Liu
Kaushal Madan
Rosmawati Mohamed
Qin Ning
Salimur Rahman
Archana Rastogi
Stephen M. Riordan
Puja Sakhuja
Didier Samuel
Samir Shah
Barjesh Chander Sharma
Praveen Sharma
Yasuhiro Takikawa
Babu Ram Thapa
Chun-Tao Wai
Man-Fung Yuen
Publikationsdatum: 01.03.2009
Verlag: Springer-Verlag
Erschienen in: Hepatology International / Ausgabe 1/2009
Print ISSN: 1936-0533
Elektronische ISSN: 1936-0541
DOI: https://doi.org/10.1007/s12072-008-9106-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2009

Usjmscp-Nih-Apasl

Free Paper Presentation

Poster Presentation

Relation of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 levels to growth retardation in extrahepatic portal vein obstruction

Young Investigator Presentation